Reunion Neuroscience, a drug company developing psychedelics for the treatment of mental health conditions, has raised tens of millions of dollars to support its research efforts.

Reunion Neuroscience是一家开发用于治疗心理健康状况的迷幻药的制药公司，已筹集数千万美元用于支持其研究工作。

MPM Capital, the biotechnology investment firm that took Reunion private last year, co-led the Series A financing alongside Novo Holdings, the parent company of pharmaceutical giant Novo Nordisk. Arkin Bio Ventures, Mitsui & Co. Global Investment, Plaisance Capital, FemHealth Ventures and Palo Santo also participated in the round, which totaled $103 million..

去年将留尼旺私有化的生物技术投资公司MPM Capital与制药巨头诺和诺德的母公司诺和诺德控股共同领导了A系列融资。Arkin Bio Ventures、Mitsui&Co.Global Investment、Plaisance Capital、FemHealth Ventures和Palo Santo也参与了这轮投资，总金额为1.03亿美元。

Reunion says the fresh funding will help pay for a mid-stage clinical trial testing its most advanced experimental medicine, code-named RE104, in women with postpartum depression. The company expects to start enrolling participants before the end of June and get results sometime in the second quarter of next year..

留尼汪说，新的资金将用于支付中期临床试验的费用，该试验测试了其最先进的实验药物，代号为RE104，用于产后抑郁症患者。该公司预计在6月底之前开始招募参与者，并在明年第二季度的某个时候取得结果。

Reunion’s medicine is, essentially, a synthetic version of psilocin, one of the compounds found in psychedelic mushrooms. Over the last several years, psychedelic drugmakers have made inroads on some of the legal, scientific and regulatory challenges that historically held back this area of research.

留尼汪的药物本质上是一种合成的裸盖菇素，它是迷幻蘑菇中发现的化合物之一。在过去几年中，迷幻药制造商已经在一些法律，科学和监管挑战方面取得了进展，这些挑战历史上阻碍了这一研究领域的发展。

The progress has, in turn, attracted more money from biotech investors..

这一进展反过来又吸引了生物技术投资者的更多资金。

In 2020, for example, an initial public offering provided Compass Pathways with nearly $150 million to continue its work testing a different compound found in many mushroom species, psilocybin, against conditions like PTSD and depression.

例如，2020年，首次公开募股为Compass Pathways提供了近1.5亿美元，以继续测试在许多蘑菇物种中发现的另一种化合物psilocybin，对抗创伤后应激障碍和抑郁症等疾病。

More recently, shares of the Australian-based biotech Incannex Healthcare spiked after a small study found psilocybin helped people with generalized anxiety disorder. Another company in the space, Cybin, in March raised $150 million by selling stock to select investors.

最近，一项小型研究发现裸盖菇素有助于广泛性焦虑症患者，澳大利亚生物技术公司Incanex Healthcare的股价飙升。该领域的另一家公司Cybin在3月份通过向精选投资者出售股票筹集了1.5亿美元。

Psychedelics aren’t new. So to build businesses around them, drugmakers are modifying these compounds or engineering synthetic alternatives that can be patentable. In Reunion’s case, RE104 is a proprietary medicine designed to induce a much shorter psychedelic experience.

迷幻药并不新鲜。因此，为了围绕它们建立业务，制药商正在修改这些化合物或设计可获得专利的合成替代品。在留尼汪的案例中，RE104是一种专有药物，旨在诱导更短的迷幻体验。

Such a feature could save patients and caregivers considerable time and resources, especially in light of recent draft guidance issued by the Food and Drug Administration.

这样的功能可以节省患者和护理人员大量的时间和资源，特别是考虑到食品和药物管理局最近发布的指导草案。

Last year, the agency laid out some of its concerns with psychedelic drug development and offered suggestions for clinical testing. According to the agency, patients receiving these drugs “remain in a vulnerable state for as long as 12 hours.” Therefore, when monitoring for safety, there should be two healthcare providers observing the patient for the duration of the treatment session..

去年，该机构阐述了其对迷幻药开发的一些担忧，并为临床试验提供了建议。根据该机构的说法，接受这些药物的患者“长达12小时处于脆弱状态”。因此，在监测安全性时，应该有两个医疗保健提供者在治疗期间观察患者。

Reunion notes how its therapy requires “only about half a day in-clinic, a significantly shorter time commitment than required for longer duration psychedelics, like psilocybin and MDMA.” The company also said that, in an early-stage study, RE104 produced a psychedelic effect “similar in intensity and quality” to psilocybin, but lasting only about half the time, or three to four hours..

留尼汪指出，其治疗方法“在临床上只需要大约半天，比持续时间更长的迷幻药（如裸盖菇素和MDMA）所需的时间要短得多。”该公司还表示，在早期研究中，RE104产生的迷幻效果“在强度和质量上与裸盖菇素相似”，但持续时间只有大约一半，即三到四个小时。

Like the rest of Reunion’s drugs, RE104 acts on a protein well-known to neuroscientists. Research indicates this protein, called serotonin 2A receptor, is tied to learning, memory as well as a range of mental disorders. It’s also what psychedelic drugs interact with to cause hallucinogenic effects.

像留尼汪的其他药物一样，RE104作用于神经科学家众所周知的蛋白质。研究表明，这种被称为血清素2A受体的蛋白质与学习、记忆以及一系列精神障碍有关。它也是迷幻药相互作用产生幻觉效应的原因。

“We see a significant opportunity for RE104 to become a best-in-class therapy and are deeply encouraged by its potential to improve outcomes for patients facing limited treatment alternatives,” said Natalie Sacks, a venture partner in the venture investments group at Novo Holdings’ U.S. division, in a statement..

Novo Holdings美国分部风险投资集团的风险投资合伙人娜塔莉·萨克斯（NatalieSacks）在一份声明中表示：“我们看到RE104成为同类最佳疗法的重大机会，并对其改善面临有限治疗选择的患者预后的潜力深感鼓舞。”

Aside from postpartum depression, Reunion is investigating whether RE104 can treat other neuropsychiatric diseases. One of interest is “adjustment disorder” in cancer, which the company defines as a “maladaptive response” to a cancer diagnosis that persists longer than two weeks and is “disproportionate to the magnitude of the stressor.” An estimated 40% of cancer patients develop a mood disorder, according to Reunion..

除了产后抑郁症，留尼汪正在研究RE104是否可以治疗其他神经精神疾病。令人感兴趣的是癌症中的“适应障碍”，该公司将其定义为对癌症诊断的“适应不良反应”，持续时间超过两周，并且“与压力源的程度不成比例”。据Reunion称，估计有40%的癌症患者患上了情绪障碍。

The financing disclosed Wednesday furthers a sort of turnaround story for Reunion, which two years ago was at risk of violating the Nasdaq stock exchange’s minimum share price requirements.

周三披露的融资情况为留尼汪带来了某种转机，两年前留尼汪有违反纳斯达克证券交易所最低股价要求的风险。

At the time, Reunion was operating as Field Trip Health. But in April 2022, the company announced it would split in two. Its drug discovery activities would become Reunion, while its healthcare business would be renamed Field Trip Health and Wellness.

当时，留尼汪是作为实地考察健康中心运作的。但在2022年4月，该公司宣布将一分为二。它的药物发现活动将成为Reunion，而其医疗保健业务将更名为FieldTrip Health and Wellness。

Once the split finalized, Reunion consolidated its shares on a 5:1 basis to stay compliant with Nasdaq’s rules.

一旦拆分完成，留尼汪以5:1的比例合并其股票，以符合纳斯达克的规定。

The company didn’t stay on the public markets for much longer, though. By May 2023, it had agreed to sell to MPM in an all-cash deal valued at just over $13 million.

不过，该公司在公开市场的时间不长。到2023年5月，该公司已同意以全现金交易的形式将其出售给MPM，价值略高于1300万美元。